Invitation to iCMLf Forum for physicians attending ASH 2017

Invitation to iCMLf Forum for physicians attending ASH 2017

Each year The Max Foundation and the International CML Foundation come together during the American Society of Hematology (ASH) Meeting to host a forum for physicians treating chronic myeloid leukemia (CML) in low resource settings. The aim is to provide resources, share programmatic updates and enable robust discussions between leading CML experts and those treating the disease in low- and middle-income countries. This year’s forum will have a new component of small group discussions to allow for a more intimate question & answer session.

If you are a physician attending ASH this year, please join us at the iCMLf Forum for Physicians from Emerging Economic Regions, carried out in partnership with The Max Foundation, on Friday 8th December at 12.30pm. The iCMLf Forum is a unique experience to discuss and share experiences from all around the world. We hope to hear yours!

The 2017 Forum features ‘Perspectives on the Management of CML’ covering the topics of Molecular Monitoring for CML and Treatment Free Remission. Speakers include Dr. Susan Branford (Australia), Dr. Katia Pagnano (Brazil) and Dr. Susanne Saussele (Germany). This year, there is an expanded format for physicians from low- and middle-income countries to “Meet the Expert” at the end of the meeting.  In the small group sessions, physicians will be able to hear from and chat with CML experts around the management of TKIs.

The iCMLf Forum for Physicians from Emerging Regions will be held:

12.30pm – 3:30 pm on Friday 8th December
at the Doubletree Downtown Atlanta, Georgia, USA

If you are traveling to ASH this year, please consider joining this meeting. Feel free to share this email and the attached invitation with your colleagues.  Please click here to reserve your place or for any queries please email melissa@cml-foundation.org.

Thanks, as always, for your support!

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • It was heartwarming looking at my son Max’s picture at the Patan Hospital: Pat Garcia-Gonzalez

    It was heartwarming looking at my son Max’s picture at the Patan Hospital: Pat Garcia-Gonzalez

    Read the interview with the Nepal Live Today – October 21, 2024.

  • The Max Foundation (Max) and the International PNH Interest Group (IPIG) Announce Collaboration to Improve Care and Management for People Living with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Low-Resource Countries

    The Max Foundation (Max) and the International PNH Interest Group (IPIG) Announce Collaboration to Improve Care and Management for People Living with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Low-Resource Countries

    IPIG joins Max’s Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT) and will provide medical education and training on PNH care and management Max will provide access to innovative treatment as part of the multi-stakeholder collaboration focused on eradicating survival disparities in 53 low-resource countries People living with this rare blood disease require frequent….

  • The Max Foundation Renews Partnership to Expand Access to Chronic Lymphocytic Leukemia Treatment

    The Max Foundation Renews Partnership to Expand Access to Chronic Lymphocytic Leukemia Treatment

    We have extended our partnership with BeOne Medicines and BeOne Care Foundation to provide access to treatment for chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively by the end of 2028. Read the full press release.